No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GKOS240517P90000
- 0.65
- 0.000.00%
15min DelayTrading May 2 10:12 ET
0.00High0.00Low
0.00Open0.65Pre Close0 Volume5 Open Interest90.00Strike Price0.00Turnover101.06%IV-17.60%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.65Time Value100Contract SizeAmericanOptions Type-0.0846Delta0.0098Gamma166.82Leverage Ratio-0.1567Theta-0.0019Rho-14.11Eff Leverage0.0242Vega
Intraday
- 5D
- 1D
News
Glaukos(GKOS.US) Officer Sells US$11,587.8 in Common Stock
$Glaukos(GKOS.US)$ Officer Gilliam Joseph E sold 105 shares of common stock on May 6, 2024 at an average price of $110.36 for a total value of $11,587.8.Source: Announcement What is statement of chang
Glaukos(GKOS.US) Officer Sells US$9,923.4 in Common Stock
$Glaukos(GKOS.US)$ Officer Thurman Alex R. sold 90 shares of common stock on May 6, 2024 at an average price of $110.26 for a total value of $9,923.4.Source: Announcement What is statement of changes
Earnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$113
It's been a pretty great week for Glaukos Corporation (NYSE:GKOS) shareholders, with its shares surging 12% to US$108 in the week since its latest quarterly results. Revenues of US$86m beat expe
Glaukos(GKOS.US) Officer Sells US$46,712.79 in Common Stock
$Glaukos(GKOS.US)$ Officer Thurman Alex R. sold 442 shares of common stock on May 2, 2024 at an average price of $105.69 for a total value of $46,712.79.Source: Announcement What is statement of chang
Glaukos(GKOS.US) Officer Sells US$217.26K in Common Stock
$Glaukos(GKOS.US)$ Officer Gilliam Joseph E sold 2,059 shares of common stock on May 2, 2024 at an average price of $105.52 for a total value of $217.26K.Source: Announcement What is statement of chan
Glaukos Raised to Buy From Hold by Jefferies
Glaukos Raised to Buy From Hold by Jefferies
Comments
Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.
Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%
Last week’s PDUFAs:
$Arcutis Biotherapeutics(ARQT.US$ :![]()
Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co(MRK.US$ : Approved 12/15![]()
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US$ : Approved 12/14![]()
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co(MRK.US$ : Approved ...
$Arcutis Biotherapeutics(ARQT.US$ :
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co(MRK.US$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co(MRK.US$ : Approved ...
7
1
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US$ $Vertex Pharmaceuticals(VRTX.US$ $OptiNose(OPTN.US$ $Arcutis Biotherapeutics(ARQT.US$ $Calliditas Therapeutics(CALT.US$ $bluebird bio(BLUE.US$ $Glaukos(GKOS.US$ $Ionis Pharmaceuticals(IONS.US$ $Amgen(AMGN.US$ $Merck & Co(MRK.US$
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US$ $Vertex Pharmaceuticals(VRTX.US$ $OptiNose(OPTN.US$ $Arcutis Biotherapeutics(ARQT.US$ $Calliditas Therapeutics(CALT.US$ $bluebird bio(BLUE.US$ $Glaukos(GKOS.US$ $Ionis Pharmaceuticals(IONS.US$ $Amgen(AMGN.US$ $Merck & Co(MRK.US$
7
2
Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.
Read more